NERISONE OILY CREAM
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
26-01-2017
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
DIFLUCORTOLONE VALERATE
Inapatikana kutoka:
GLAXOSMITHKLINE INC
ATC kanuni:
D07AC06
INN (Jina la Kimataifa):
DIFLUCORTOLONE
Kipimo:
0.1%
Dawa fomu:
CREAM
Tungo:
DIFLUCORTOLONE VALERATE 0.1%
Njia ya uendeshaji:
TOPICAL
Vitengo katika mfuko:
3G/30G/60G
Dawa ya aina:
Prescription
Eneo la matibabu:
ANTI-INFLAMMATORY AGENTS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0115864001; AHFS:
Idhini hali ya:
CANCELLED POST MARKET
Idhini ya tarehe:
2016-09-30
Tabia za bidhaa
_ _
_Page 1 of 19_
PRODUCT MONOGRAPH
PR
NERISONE
®
(DIFLUCORTOLONE VALERATE)
Oily Cream 0.1% w/w
GSK Standard
Topical Corticosteroid
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Revision:
January 26, 2017
Submission Control No: 200095
_©2017 GSK Inc., All Rights Reserved _
_NERISONE is a trademark of Bayer Schering Pharma Aktiengesellschaft,
used under license by GSK Inc. _
_ _
_ _
_Page 2 of 19_
TABLE OF CONTENTS
_ _
_ _
PAGE
PART I: HEALTH PROFESSIONAL
INFORMATION................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
INDICATIONS AND CLINICAL USE
.........................................................................
3
CONTRAINDICATIONS
..............................................................................................
3
WARNINGS AND PRECAUTIONS
.............................................................................
4
ADVERSE REACTIONS
...............................................................................................
8
DRUG INTERACTIONS
...............................................................................................
8
DOSAGE AND ADMINISTRATION
...........................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
....................................................... 10
STORAGE AND STABILITY
.....................................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................ 11
PART II: SCIENTIFIC INFORMATION
........................................................................
13
PHARMACEUTICAL INFORMATION
.....................................................................
13
REFERENCES
.............................................................................................................
16
PART III: CONSUMER INFORMATION
......................................................................
17
_ _
Soma hati kamili
